Amvuttra Interactions
No drug interactions were found for Amvuttra (vutrisiran). However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Amvuttra (vutrisiran) is in the drug class miscellaneous metabolic agents. Amvuttra (vutrisiran) is used to treat the following conditions: Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Hereditary Amyloidosis, Transthyretin-Related Amyloidosis.
Amvuttra disease interactions
There are 2 disease interactions with Amvuttra (vutrisiran) which include:
Report options
More about Amvuttra (vutrisiran)
- Amvuttra consumer information
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous metabolic agents
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Attruby
Attruby (acoramidis) tablets are used to treat cardiomyopathy of wild-type or hereditary ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Tegsedi
Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Onpattro
Onpattro is used to treat polyneuropathy in adults with hereditary transthyretin-mediated ...
Eplontersen
Eplontersen (Wainua) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Patisiran
Patisiran (brand name Onpattro) is an injectable treatment for polyneuropathy caused by hereditary ...
Acoramidis
Acoramidis systemic is used for cardiomyopathy of transthyretin-mediated amyloidosis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
